{"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"31"}],"units":"Participants"}],"groups":[{"description":"Participants received vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.","id":"BG000","title":"Level 1: Vorinostat 300 mg + Lenalidomide 10 mg"},{"description":"Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.","id":"BG001","title":"Level 2: Vorinostat 400 mg + Lenalidomide 10 mg"},{"description":"Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.","id":"BG002","title":"Level 3: Vorinostat 400 mg + Lenalidomide 15 mg"},{"description":"Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.","id":"BG003","title":"Level 4: Vorinostat 400 mg + Lenalidomide 20 mg"},{"description":"Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle. Treatment continued until progressive disease or unacceptable toxicity.","id":"BG004","title":"Level 5: Vorinostat 400 mg + Lenalidomide 25 mg"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.7","value":"69.5"},{"groupId":"BG001","spread":"2.1","value":"58.5"},{"groupId":"BG002","spread":"6.1","value":"66.3"},{"groupId":"BG003","spread":"2.5","value":"55.7"},{"groupId":"BG004","spread":"7.2","value":"64.1"},{"groupId":"BG005","spread":"7.0","value":"63.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"13"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"18"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}